LogicBio Therapeutics, Inc. announced the appointment of Richard Moscicki, M.D. and Michael Wyzga to its Board of Directors. The two are accomplished leaders in the field and individually have decades of strategic and operational management experience. Both have extensive knowledge of rare disease drug development and bring rich insight in the areas of clinical research, regulatory affairs and corporate governance to the board. Moscicki has more than 25 years of experience in drug development and is currently the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). Michael Wyzga is a leader in the biotech community and joins LogicBio's Board of Directors as the chair of the audit committee. Currently, Wyzga is the CEO and President of MSW Consulting, Inc.